FORT LAUDERDALE, Fla., June 13, 2017 -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, has been selected to provide electronic data capture (EDC) software and services to a major contract research organization (CRO) with locations in the U.S. and Europe. Under the terms of the deal, the CRO will utilize OmniComm’s TrialOne® system to standardize clinical development programs, ensure regulatory compliance and bring greater operational efficiency, speed and quality to the clinical research process within its clinics.
”With this project award, TrialOne’s position as the market-leading eSource solution for Phase I clinics is now solidified,” said Kuno van der Post, OmniComm’s chief commercial officer. “We are absolutely thrilled to have been selected, more so as it comes after a period of significant investment within OmniComm in both product quality and highly skilled support resources. The timing could not have been better.”
The CRO will use TrialOne to implement a number of automated clinical trial processes across multiple clinics, including the recruitment and screening of subject participants, study design and the collection, analysis and reporting of data. Future project initiatives will include multiple interfaces with clinic equipment such as blood pressure sensors and electrocardiogram (ECG) devices.
TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early-phase research clinics. As the market-leading early-phase research clinical eSource system, TrialOne addresses the following needs of this CRO:
- Manage and optimize patient screening and recruitment.
- Implement data capture from subject bedside.
- Automate data capture from medical monitoring equipment and devices.
- Streamline staff training and support records.
- Integrate with laboratory information management systems (LIMS) for lab orders and lab results processing.
Supporting Information
- TrialOne
- eSource Easier than You Think - Whitepaper
- OmniComm Systems Achieves Major Milestone with Over 1,500 Active TrialOne Users Worldwide
- OmniComm Systems® Signs Multi-Year Agreement with Top 5 Global CRO for TrialOne®
- Seoul National University Hospital Signs Five Year Agreement with OmniComm Systems® TrialOne® for Clinical Research Automation
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience, based on more than 5,000 clinical trials. For more information, please visit: omnicomm.com
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 [email protected]


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



